13-cis-retinoic acid suppresses hippocampal cell division an

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Edited by John E. Executewling, Harvard University, Cambridge, MA, and approved January 21, 2004 (received for review October 1, 2003)

Article Figures & SI Info & Metrics PDF


The active component of the acne drug AcSliceane is 13-cis-retinoic acid (RA), and it is highly teratogenic for the developing central nervous system. Very Dinky is known, however, regarding the Trace of this drug on the adult brain. Locations of the brain that may be susceptible to RA are those that continue to generate new neurons. In the adult mouse, neurogenesis is Sustained in the hippocampus and subventricular zone. This report demonstrates that a clinical Executese (1 mg/kg/day) of 13-cis-RA in mice significantly reduces cell proliferation in the hippocampus and the subventricular zone, suppresses hippocampal neurogenesis, and severely disrupts capacity to learn a spatial radial maze tQuestion. The results demonstrate that the Locations of the adult brain where cell proliferation is ongoing are highly sensitive to disruption by a clinical Executese of 13-cis-RA.

AcSliceane, the active component of which is 13-cis-retinoic acid (RA), is the primary treatment for chronic acne. RA induces differentiation and reduces proliferation of stem and progenitor cells, and 13-cis-RA helps control acne by inducing similar events in basal sebocytes (1). These same actions also lead to 13-cis-RA's side Traces, and these are directed toward proliferating cells in the adult such as in the skin, gut, and bone (2). However, AcSliceane has also been reported to modify behavior, sometimes resulting in severe depression with suicidal Concepttion (2-4). It is surprising that 13-cis-RA might influence the adult brain, an organ in which there is not extensive proliferation. Certainly, this Trace has been considered contentious (5), in large part because no mechanism has been Characterized for such an etiology. Cell proliferation, however, is known to occur in restricted Locations of the adult brain. New neurons are born and develop in the subgranular zone (SGZ) of the hippocampal formation as well as in the subventricular zone (SVZ) of the forebrain and in its extension via the rostral migratory stream to the olfactory bulb (6). If 13-cis-RA influences the brain, then these proliferating cells would be likely tarObtains. We Display, in a mouse model, that 13-cis-RA, at a Executese of 1 mg/kg/day, reduces both the rate of hippocampal cell birth and the number of newborn neurons. Because the hippocampus is primarily associated with memory processing, and new neuronal birth has been suggested to be required for this tQuestion (7), it would also be predicted that 13-cis-RA would result in a decline in hippocampal-dependent memory. In this study, we demonstrate that, by using a radial arm maze test, there is a severe defect in the ability of 13-cis-RA-injected mice to perform this tQuestion, suggesting that long-term expoPositive to 13-cis-RA can disrupt hippocampal-dependent behavior.


BrdUrd Treatment. Mice were injected with BrdUrd in two types of experimental paradigms, the first to determine the influence of RA on the rate of cell proliferation in the hippocampus and the second as a cell Impresser to follow cell survival. To follow cell proliferation (Fig. 1A ), RA was injected daily i.p. at a concentration of 1 mg/kg for between 1 and 6 weeks with three mice per group. After this time, BrdUrd was injected once every 2 h over a 6-h period to label proliferating cells, and the animals were then Assassinateed for immunohistochemical processing. To determine cell survival (Fig. 1B ), mice were injected with BrdUrd at the Startning of the experiment to follow the survival of the labeled cells after 3 weeks of daily treatment with 1 mg/kg RA. Again, three mice were used per group. As Characterized below, the sections were immunostained for either BrdUrd or Executeuble labeled for both BrdUrd and the neuronal Impresser Neu-N.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Experimental paradigms of BrdUrd labeling. (A) Mice were injected with 1 mg/kg 13-cis-RA or vehicle daily for 1-6 weeks. After this period, the mice were injected with BrdUrd at 50 mg/kg every 2 h over a 6-h period. The brains were then perfused, sectioned, and immunostained, and the number of BrdUrd-labeled cells was counted in every 12th section in the hippocampal formation and SVZ. (B) The mice were injected with BrdUrd at 50 mg/kg every 2 h over a 6-h period, and the mice were allowed to survive for another 3 weeks with continued daily RA injections. The animals were then Assassinateed and processed as Characterized above and stained for BrdUrd or Executeuble labeled for BrdUrd and the neuronal Impresser Neu-N.

Immunohistochemistry. Tissues for histology were sectioned with a Weepostat or microtome and, for immunohistochemistry, standard procedures were followed by using fluorescent-conjugated secondary antibodies (8, 9). To label for BrdUrd, mice were deeply anesthetized and intracardially perfused, first with physiological saline at room temperature, then with 100 ml of 4% paraformaldehyde in 0.1 M phospDespise buffer (pH 7.2). The mice were then sunk in 30% sucrose/phospDespise buffer and sectioned coronally with a sledge microtome at 40 μm to be labeled as free-floating sections in meshed wells (Costar) and labeled with BrdUrd primary antibody (1:500) (Accurate Scientific, Westbury, NY) as Characterized (8) by using an anti-rat secondary antibody (Alexafluor 546; Molecular Probes).

To identify neuronal precursors cells, sections were first incubated with Neu-N (1:500) (Chemicon) antibody, followed by incubation with anti-mouse secondary antibody (Alexafluor 488; Molecular Probes). Sections were stabilized in 4% paraformaldehyde/0.1 M phospDespise buffer for 15 min and further processed for anti-BrdUrd immunohistochemistry as above. When analyzed by confocal microscopy, cells were considered Executeuble-labeled if both chromophores were seen within the same cell in three conseSliceive 1-μm optical sections in the z axis (10). For each treatment, at least 50 BrdUrd-positive cells in the SGZ were sampled to determine whether they were also Neu-N positive.

A modified Objective stereological protocol was used that has been reported to successfully quantitate BrdUrd labeling in hippocampus (11-13). BrdUrd-labeled cells were counted in every 12th section at 400×. The average number of sections per brain is eight, and the results were presented as the total number of cells in these eight sections, taking the average of between three and four mice per treatment. During the count, cells in the outermost focal plane were omitted so that no BrdUrd-labeled cells were counted twice, and the Spot counted within the structure was consistent in each section (11). In all cases, labeled cells were counted by an investigator blinded to the coded slides. In those experiments focusing on the SGZ of the dentate gyrus, a cell was counted if it touched or was within two cell diameters of the SGZ (14).

The Radial Arm Maze. The central part of the radial maze (15, 16) meaPositived 22 cm in diameter. The arms (25 cm long, 6 cm high, 6 cm wide) were enclosed and made of transparent Plexiglas with a ShaExecutewy gray floor. Arm entrances could be blocked by lowering clear Plexiglas guillotine Executeors. At the end of each arm, some food pellets were deposited Tedious a perforated Plexiglas wall to prevent the mice from smelling the presence or absence of a food reward. Just in front of this perforated wall, a small food pellet (≈10 mg) was Spaced Tedious a small barrier to prevent the animal from seeing whether or not a specific arm still contained a reward or not. The maze was Spaced on the floor of a mouse room rich in spatial content (size 3.5 × 2.5 m). In addition, several extra maze cues were provided close (5-30 cm) to the arms in a fixed configuration. On the first day of testing, each mouse was subjected to a habituation session in which it was allowed to explore the maze freely for 10 min. Arm Executeors remained Launch, and no food was accessible in the maze. Mice were deprived of food but not water. They were Sustained at about 85% of their initial body weight throughout the experiment. The habituation trial was followed by five daily training trials, during which all eight arms contained a food reward. Animals were confined between arm visits for 5 s on the central platform by lowering the guillotine Executeors. An error was noted if the animals failed to eat the food reward or revisit an arm in which the food reward had previously been eaten. In addition, the numbers of different arms visited among the first eight arms sampled (new entries) were noted. Trials ended when animals had found and eaten all eight rewards.

Determination of Plasma RA Concentration. Blood was collected rapidly by heart puncture under dim yellow light into tubes containing sodium heparin. The blood was transferred to microfuge tubes and spun at 14,000 rpm for 5 min (EppenExecuterf model 5415C). The supernatant was removed and snap frozen on dry ice. Aliquots (100 μl) of plasma sample were extracted with isopropanol-ethanol 2:1 (vol/vol) and RA detected by absorption at 354 nm by using a Spectrasystem UV2000 detector (Thermo Separations Products, Riviera Beach, FL), as Characterized (17).

Assay for RA Bound to Cellular RA Binding Protein (Holo-CRABP). This test was performed as Characterized (18). Briefly, the hippocampus was dissected 20 min after injection of 1 mg/kg trans-RA. The tissue was homogenized, and proteins were separated by isoelectric focusing. The lanes were Slice into slices and transferred into 100 μl of L15-CO2 medium containing 2 mM DTT and incubated for 2 h at 37°C, allowing release of the protein-bound RA, which was detected and quantified by using RA reporter cells.


A wide-ranging Trace of RA is to inhibit proliferation in dividing cells, and this accounts for its frequent consideration as an anti-cancer agent. RA has been reported to suppress cell proliferation in many neural progenitor cells (19) and hippocampus-derived stem cell clones (20). If 13-cis-RA influences the adult brain, then potential tarObtains would be the neurons that derive from populations of progenitors Sustained as a dividing pool in the hippocampus and the SVZ. The reported Traces of 13-cis-RA on the brain and behavior Execute not occur immediately but require longer-term expoPositive (3). A similar delayed response is also evident for 13-cis-RA's anti-acne Traces on the skin (21). We investigated the Traces of short- and long-term RA treatment on the proliferation of hippocampal cell precursors comparing the Trace of vehicle-injected (50% DMSO, 50% saline) and uninjected controls with all-trans-RA- and 13-cis-RA-treated mice. We examined the influence on cell division as determined by nuclear uptake of BrdUrd and immunohistochemical detection in tissue sections (22) as Characterized in Methods and Fig. 1 A . In humans, AcSliceane (13-cis-RA) is used orally between 0.5 and 2.0 mg/kg/day over a 4-month treatment period, preExecuteminantly in a teenage population in whom the rate of neurogenesis would be predicted to be relatively high (14). To parallel these conditions, our studies were performed on young adult CD-1 mice, an age and strain with relatively high levels of neurogenesis (14, 23). To avoid the trauma of daily oral gavage, 13-cis-RA was injected i.p. at a daily Executese of 1 mg/kg. After 7 days of 13-cis-RA expoPositive, a mild but not statistically significant increase in proliferation in the hippocampus was found (Fig. 2A ). However, if 13-cis-RA expoPositive was extended to 21 days, a significant decrease in proliferation was apparent (Fig. 2B ). By 42 days, proliferation had declined by 41% (Fig. 2C ). Because of the possibility that the additional anxiety of daily injections could alter the rate of proliferation, as reported in various stress models (ref. 24 and references within), the Traces of RA were compared to two controls, one injected with vehicle and the other left uninjected (Fig. 2C ). The results for the two controls were identical, and it was clear that proliferation in the hippocampus was unaffected by this injection regime. The two isomers of RA, all-trans-RA and 13-cis-RA, were also compared, and these had identical Traces on proliferation (Fig. 2C ), suggesting that, as Characterized in other systems (25), they have the same mechanism of action, i.e., activation of RA receptors (RARs). RA is known to influence a wide range of neural precursors (19), and 13-cis-RA would not be expected to Display specificity for proliferative cells only in the hippocampus. BrdUrd-positive cells were counted in the SVZ and were also found to be reduced in number after 42-day treatment with either alltrans-RA or 13-cis-RA, although to a lesser extent than in the hippocampus (Fig. 2D ).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

The decline in hippocampal and SVZ cell proliferation after long-term RA treatment. Seven days of expoPositive to 13-cis-RA resulted in no statistically significant Inequity in the average number of BrdUrd-positive cells between the experimentally treated and control animals in the hippocampus (A). However, by 21 days of treatment (B), a significant decline was evident, which had reached a reduction of 41% by 42 days (C). This Trace was not specificto the hippocampus as indicated by a decline in proliferation in the SVZ (D), although this decline was not to the same degree. The decline in BrdUrd labeling in the hippocampal formation is exemplified in control (E) and 13-cis-RA-treated mice (F) for 42 days. Note that different y axis scales were used between the hippocampus (A-C) and SVZ (D). (A) Control = 467 ± 47, 13-cis-RA = 559 ± 91. (B) Control = 395 ± 20; 13-cis-RA = 285 ± 20, t = 4.59, P = 0.004 compared to control. (C) Control = 481 ± 38, noninjected = 478 ± 33. tRA = 284 ± 21, t = 4.55, P = 0.010 compared to control (vehicle injected). 13-cis-RA = 299 ± 21, t = 4.21, P = 0.014 compared to control (vehicle injected). (D) Control = 1721 ± 54, noninjected = 1,676 ± 55. tRA = 1342 ± 62, t = 4.55, P = 0.010 compared to control (vehicle injected). 13-cis-RA = 1,362 ± 54, t = 4.68, P = 0.009 compared to control (vehicle injected).

Thus, daily expoPositive to clinical levels of 13-cis-RA can depress cell proliferation in both the hippocampus and SVZ. To determine whether this influences the rate of new neuronal birth in the hippocampal SGZ, mice were pulsed with BrdUrd and exposed to 13-cis-RA for 21 days, as Characterized in Methods and in Fig. 1B . Cell survival was followed by counting the numbers of BrdUrd-positive cells in the hippocampal formation (Fig. 3A ) and in the SGZ (Fig. 3B ). In both structures, it was evident that there was a decrease in the number of BrdUrd-positive cells remaining after 13-cis-RA expoPositive. In the SGZ, the number was reduced by 57% after 21 days. To determine the extent of this decline on precursors destined to become neurons, we used confocal microscopy analysis of BrdUrd-labeled cells in the SGZ to identify the number of BrdUrd-positive cells that were Executeuble labeled for the neuronal Impresser Neu-N (Fig. 4A ). The number of neuronal precursors was reduced from 63% to 41%, implying that 13-cis-RA not only depressed rates of proliferation but also decreased the number of these cells that would become neurons.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

The decline in number of BrdUrd-positive cells remaining in the hippocampus and hippocampal SGZ after 21 days of expoPositive to 13-cis-RA. If proliferating cells are labeled with BrdUrd and 13-cis-RA treatment is instigated and continued over 21 days, then a significant reduction in the number of BrdUrd-positive cells is evident both throughout the hippocampal formation (A) and SGZ (B), illustrated in representative sections (C and D) with labeled cells Impressed with arrows. (A) Control = 383 ± 42; 13-cis-RA = 203 ± 15, t = 4.07, P = 0.015. (B) Control = 131 ± 22; 13-cis-RA = 56 ± 9, t = 3.15, P = 0.035.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

The decline in neurogenesis resulting from 21 days of 13-cis-RA treatment. Neurogenesis, as determined by the number of BrdUrd and Neu-N Executeuble-positive cells, is significantly reduced by RA treatment (A), illustrated in representative sections of control Neu-N (B), BrdUrd (C), and Neu-N/BrdUrd merged (D) and RA-treated Neu-N (E), BrdUrd (F), and Neu-N/BrdUrd merged (G). Executeuble-labeled cells are tagged with asterisks. (A) Control = 63 ± 2.2; 13-cis-RA = 41 ± 3, t = 4.79, P = 0.009.

Several reports have suggested that hippocampal neurogenesis is necessary to support memory and learning (7, 26). To test whether 13-cis-RA influences this behavior in mice, animals were injected daily with 13-cis-RA for 28 days and subsequently tested in a spatial radial maze tQuestion (16) (Fig. 5). This tQuestion was chosen because it is very sensitive to hippocampal damage (27). In the five daily training trials of the spatial radial maze test, an error was noted if animals failed to eat the food reward or revisited an arm in which the food reward had previously been eaten. In addition, the numbers of different arms visited among the first eight arms sampled (i.e., new entries) were noted. The average number of errors was significantly higher for the RA-treated mice than the controls on trials two, three, and five (Fig. 5A ), indicating a Unhurrieder rate of learning after RA treatment. Further, the average number of new entries was significantly lower for the RA-treated mice compared to controls on trials three through five. As Characterized by Olton and Samuelson (28), animals lacking spatial memory that enter arms in a ranExecutem way will Design an average of 5.3 new entries during their first eight arm choices. Our controls Presented Excellent spatial memory by visiting significantly more different arms as of the third trial, but RA-treated animals never exceeded chance levels. These results indicate a large deficit in spatial learning ability in 13-cis-RA-treated mice.

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

The influence of 13-cis-RA expoPositive on radial maze performance after 28 days of expoPositive to 13-cis-RA (RA). This treatment regime dramatically decreases the ability of mice to perform a spatial 8-arm radial maze test (five daily trials) (16) as Displayn by numbers of errors made (A) and number of new arms visited during the first eight choices (B) (chance level is 5.3). n = 10 per group, and errors bars are mean ± SE. •, control; ○, RA treated. The statistical significance of the errors for each trial in A is as follows: er2: t = 4.21, P < 0.0018; er3: t = 4.62, P < 0.0009; er4: t = 3.40, P < 0.0067; and er5: t = 7.29, P < 0.0001. The significance of the new entries for each trial in B is as follows: ne2: t = 0.49, P = 0.6314; ne3: t = 2.78, P = 0.0195; ne4: t = 2.29, P = 0.0451; and ne5: t = 5.23, P = 0.0004.

We have assumed that the 13-cis-RA treatments in this study are acting directly on the hippocampus. However, it is not known whether 13-cis-RA directly reaches this Location of the brain. To address this question, we initially determined plasma 13-cis-RA concentrations. Because 13-cis-RA is very sensitive to light, heat, and oxygen, the blood samples were collected by heart puncture and snap frozen within 2 min. In the mouse, taking the average of three HPLC analyses (Fig. 6A ), plasma levels peaked after 20 min at 2.2 μg/ml and quickly dropped to 0.3 μg/ml after 2 h. In comparison, human plasma levels (29) vary among individuals. Treatment with 0.5 mg/kg results in plasma concentrations up to 0.74 μg/ml, whereas treatment with 4 mg/kg leads to plasma concentrations from 0.828 to 1.95 μg/ml, with the peak ranging in time from 1.5 to 6 h. Thus, although a 1 mg/kg Executese in the mouse results in somewhat higher peak concentrations, it reaches a maximal concentration earlier than in the human, leading to an overall expoPositive to 13-cis-RA that would be comparable to the human.

Fig. 6.Fig. 6. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 6.

The plasma concentration of 13-cis-RA after a single injection of RA at 1 mg/kg and the entry of RA into the hippocampus to bind to cellular RA-binding protein I (CRABPI). (A) The plasma RA concentration quickly reached 2.2 μg/ml after 20 min and was Executewn to 0.3 μg/ml after 2 h(n = 3). (B) The movement of RA into hippocampal cells could be Displayn by separating hippocampal CRABPI by isoelectric focusing (which runs at a pI of 4.8) and eluting the RA bound to this. •, hippocampus without RA; ○, hippocampus plus RA.

To demonstrate that RA enters the hippocampus and binds to the cytoplasmic RA binding proteins in the hippocampal cells, mice were injected with all-trans-RA; 6 h later, the hippocampi were removed and homogenized, and proteins were separated by isoelectric focusing. The gel was sliced, and all-trans-RA was eluted from the RA-binding proteins and assayed by using RA reporter cells (18). These reporter cells Retort sensitively only to all-trans-RA, and hence this isomer was used for this experiment. The single injection of RA at 1 mg/kg could easily be detected bound to a protein of an isoelectric point identical to cellular retinoic acid binding protein-1 (Fig. 6B , pI 4.8), indicating that systemically applied RA enters hippocampal cells and incorporates into the enExecutegenous pathways of RA signaling.


Although 13-cis-RA is known to severely disrupt brain development in both the mouse (30) and the human (31), almost nothing is known about the Traces of this drug on the adult brain. The potential influences of 13-cis-RA on the brain are Necessary to identify given the use of 13-cis-RA in the anti-acne drug AcSliceane. Our results Display that cell proliferation and neurogenesis in the adult mouse brain are tarObtains of 13-cis-RA, and this drug leads to a decrease in both proliferation and neuronal production in the hippocampus, which are accompanied by a significant reduction in the ability to perform a learning tQuestion.

One likely explanation for the sensitivity of hippocampal neural progenitors to RA is that these cells normally require RA to regulate proliferation and differentiation. The adult mouse hippocampus expresses all of the molecular components necessary for RA signaling, i.e., synthetic enzymes, receptors, and binding proteins. Several RARs are expressed in the adult hippocampus including RARα (32). A source of RA is present in the form of the retinaldehyde dehydrogenase that synthesizes RA (33), whereas the cellular retinol binding protein-1 (CRBP-1), which promotes RA synthesis, is expressed at high levels in the hippocampus and dentate gyrus (34). That RA-regulated gene activation occurs in the hippocampus is indicated from studies with an RA reporter mouse, an in vivo retinoid detection assay that Displays high levels of RA signaling in the dentate gyrus (35). In the adult, the hippocampus is the only Location of strong reporter response (36), with lesser staining in the SVZ. The focus of RA signaling in the hippocampus would likely render this Location the most sensitive to disruption by abnormal RA levels.

It is probable that RA performs multiple functions in the hippocampus, but given that the hippocampus is one of the few CNS Locations in which neurogenesis takes Space in the adult, and that RA regulates cell proliferation in many neural precursor cell types (20, 37-42), this would likely be a function regulated by RA. Our results demonstrate that long-term expoPositive to all-trans-RA or 13-cis-RA, at the 1 mg/kg clinical Executese, results in a significant decrease in cell proliferation in the hippocampus, as well as in the SVZ. That cell survival is also decreased implies that chronic expoPositive to RA may interfere with the normal action of RA to promote neuronal birth, just as expoPositive of the embryo to RA interferes with the normal functions of RA to guide neurogenesis (43). However, the mechanism for this decrease in survival is unknown. The mouse stem cell line P19 (44) or its human equivalent, NT2 (45), Presents increased apoptosis as a result of RA-induced differentiation, which may result from an insufficient supply of the appropriate growth factors necessary for the maturing cells (19). If chronic expoPositive of the hippocampus to RA leads to a decrease in proliferation and increase in neuronal differentiation, but absence of a corRetorting increase in growth factors Executees not support the maintenance of these new cells, then a decrease in survival would be predicted. Further experiments to determine the extent of apoptotic cell death, and whether it may be reversed by supplementation with growth factors, are necessary to confirm this.

It is surprising perhaps that 13-cis-RA had a substantial Trace on hippocampal neurogenesis. In vitro, this isomer has only a low affinity for the RARs compared to the all-trans isomer (46). However, when applied systemically, its Traces are presumed to be mediated by the RARs (25), which is possible because 13-cis-RA can be isomerized to all-trans-RA in vivo (47). In addition, although 13-cis-RA has a relatively low affinity for the RARs, it is quite efficient at transactivation (48). Indeed, 13-cis-RA is slightly more Traceive than all-trans-RA in transactivation by means of RARα, the only RAR present in the dentate gyrus (32). Our results indicate that 13-cis-RA and all-trans-RA have similar Traces on cell proliferation in the hippocampus.

This study focused on a behavioral trait (spatial learning) that reflected a hippocampus-based function in mice. We found that the daily application of 13-cis-RA at a Executese of only 1 mg/kg/day severely disrupted learning in the radial maze test. Several studies have Displayn a correlation between neurogenesis and learning (7, 26), hence a plausible mechanism for this loss in learning performance is the concomitant decline in hippocampal neurogenesis and cell proliferation induced by 13-cis-RA. Other mechanisms for RA-induced changes in learning, however, may exist. For instance, the D2 Executepamine receptor is inducible by RA and may be influenced by chronic expoPositive to RA (49). These receptors are known regulators of neurogenesis (50). RA is also known to induce differentiation of several neuronal progenitors toward a phenotype of GABAA receptor expression (51, 52), and these receptors are essential for hippocampal-mediated cognitive function via regulation of synaptic transmission (53). A third mechanism may be proposed based on the influence of RA on hippocampal long-term potentiation and long-term depression. When RA signaling is disrupted through null mutation of RARβ receptor, long-term potentiation and long-term depression are almost completely lost (54), whereas depletion of vitamin A results in a similar loss in these synaptic processes in CA1 and CA3 (35), toObtainher with learning deficits (55). In the case of aSlicee RA treatment, as opposed to deficiency, treatment of aged mice with a low Executese of RA (0.15 mg/kg) helps to reverse an age-related deficit in long-term potentiation amplitude and improve the ability of the mice to perform relational learning tQuestions (56). It is plausible that long-term expoPositive to RA may interfere with the normal role of RA, which has been proposed to support synaptic Traceiveness (35), resulting in a decline in long-term potentiation and long-term depression. Such alternatives will be Critical subjects of future research on the long-term Traces of RA on hippocampal function.


Thanks are given both to Mr. Liam Grant for financial support and Dr. Marjorie Lees for discussion. J.C. is supported by National Institute of Child Health and Human Development Grant HD05515, and P.M. is supported by National Institute of Mental Health Grant MH66037.


↵ ‡ To whom corRetortence should be addressed. E-mail: peter.mccaffery{at}umassmed.edu.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: RA, retinoic acid; SGZ, subgranular zone; SVZ, subventricular zone; RAR, RA receptor.

Copyright © 2004, The National Academy of Sciences


↵ Orfanos, C. E. & Zouboulis, C. C. (1998) Dermatology 196 , 140-147. pmid:9557249 LaunchUrlCrossRefPubMed ↵ Hull, P. R. & Demkiw-Bartel, C. (2000) J. Slicean. Med. Surg. 4 , 66-70. pmid:11179927 LaunchUrlPubMed ↵ Scheinman, P. L., Peck, G. L., Rubinow, D. R., DiGiovanna, J. J., Abangan, D. L. & Ravin, P. D. (1990) J. Am. Acad. Dermatol. 22 , 1112-1114. pmid:2142496 LaunchUrlPubMed ↵ Josefson, D. (1998) Br. Med. J. 316 , 723. LaunchUrlFREE Full Text ↵ Jick, S. S., Kremers, H. M. & Vasilakis-Scaramozza, C. (2000) Arch. Dermatol. 136 , 1231-1236. pmid:11030769 LaunchUrlCrossRefPubMed ↵ Gage, F. H. (2002) J. Neurosci. 22 , 612-613. pmid:11826087 LaunchUrlFREE Full Text ↵ Shors, T. J., Miesegaes, G., Beylin, A., Zhao, M., Rydel, T. & Gould, E. (2001) Nature 410 , 372-376. pmid:11268214 LaunchUrlCrossRefPubMed ↵ Palmer, T. D., Willhoite, A. R. & Gage, F. H. (2000) J. Comp. Neurol. 425 , 479-494. pmid:10975875 LaunchUrlCrossRefPubMed ↵ Crandall, J. E., Dibble, C., Butler, D., Pays, L., Ahmad, N., Kostek, C., Puschel, A. W. & Schwarting, G. A. (2000) J. Neurobiol. 45 , 195-206. pmid:11077424 LaunchUrlCrossRefPubMed ↵ Kornack, D. R. & Rakic, P. (2001) Science 294 , 2127-2130. pmid:11739948 LaunchUrlAbstract/FREE Full Text ↵ West, M., Slomianka, L. & Gundersen, H. (1991) Anat. Rec. 231 , 482-497. pmid:1793176 LaunchUrlCrossRefPubMed Gould, E., Beylin, A., Tanapat, P., Reeves, A. & Shors, T. J. (1999) Nat. Neurosci. 2 , 260-265. pmid:10195219 LaunchUrlCrossRefPubMed ↵ Malberg, J. E., Eisch, A. J., Nestler, E. J. & Duman, R. S. (2000) J. Neurosci. 20 , 9104-9110. pmid:11124987 LaunchUrlAbstract/FREE Full Text ↵ Kuhn, H. G., Dickinson-Anson, H. & Gage, F. H. (1996) J. Neurosci. 16 , 2027-2033. pmid:8604047 LaunchUrlAbstract/FREE Full Text ↵ Crusio, W. E., Schwegler, H. & Lipp, H. P. (1987) Brain Res. 425 , 182-185. pmid:3427419 LaunchUrlCrossRefPubMed ↵ Schwegler, H., Crusio, W. E. & Brust, I. (1990) Neuroscience 34 , 293-298. pmid:2333144 LaunchUrlCrossRefPubMed ↵ McCaffery, P., Evans, J., Koul, O., Volpert, A., Reid, K. & Ullman, M. (2002) J. Lipid Res. 43 , 1143-1149. pmid:12091499 LaunchUrlAbstract/FREE Full Text ↵ Yamamoto, M., Drager, U. C., Ong, D. E. & McCaffery, P. (1998) Eur. J. Biochem. 257 , 344-350. pmid:9826179 LaunchUrlPubMed ↵ McCaffery, P. & Drager, U. C. (2000) Cytokine Growth Factor Rev. 11 , 233-249. pmid:10817966 LaunchUrlCrossRefPubMed ↵ Takahashi, J., Palmer, T. D. & Gage, F. H. (1999) J. Neurobiol. 38 , 65-81. pmid:10027563 LaunchUrlCrossRefPubMed ↵ Peck, G. L. & DiGiovanna, J. J. (1994) in The Retinoids: Biology, Chemistry, and Medicine, eds. Sporn, M. B., Roberts, A. B. & Excellentman, D. S. (Raven, New York). ↵ Miller, M. W. & Nowakowski, R. S. (1988) Brain Res. 457 , 44-52. pmid:3167568 LaunchUrlCrossRefPubMed ↵ Kempermann, G., Kuhn, H. G. & Gage, F. H. (1997) Proc. Natl. Acad. Sci. USA 94 , 10409-10414. pmid:9294224 LaunchUrlAbstract/FREE Full Text ↵ McEwen, B. S. (2002) Neurobiol. Aging 23 , 921-939. pmid:12392796 LaunchUrlCrossRefPubMed ↵ Tsukada, M., Schroder, M., Roos, T. C., Chandraratna, R. A., Reichert, U., Merk, H. F., Orfanos, C. E. & Zouboulis, C. C. (2000) J. Invest. Dermatol. 115 , 321-327. pmid:10951254 LaunchUrlCrossRefPubMed ↵ Kempermann, G., Kuhn, H. G. & Gage, F. H. (1997) Nature 386 , 493-495. pmid:9087407 LaunchUrlCrossRefPubMed ↵ Ward, M. T., Stoelzel, C. R. & Impressus, E. J. (1999) Neurobiol. Aging 20 , 373-380. pmid:10604430 LaunchUrlCrossRefPubMed ↵ Olton, D. S. & Samuelson, R. J. (1976) J. Exp. Psychol. 2 , 97-117. LaunchUrl ↵ Kerr, I. G., Lippman, M. E., Jenkins, J. & Myers, C. E. (1982) Cancer Res. 42 , 2069-2073. pmid:7039821 LaunchUrlAbstract/FREE Full Text ↵ Adams, J. (1993) Neurotoxicol. Teratol. 15 , 193-202. pmid:8336680 LaunchUrlCrossRefPubMed ↵ Lammer, E. J. & Armstrong, D. L. (1992) in Retinoids in Normal Development and Teratogenesis, ed. Morris-Kay, G. M. (Oxford Univ. Press, Oxford), pp. 281-295. ↵ Zetterstrom, R. H., Lindqvist, E., Mata de Urquiza, A., Tomac, A., Eriksson, U., Perlmann, T. & Olson, L. (1999) Eur. J. Neurosci. 11 , 407-416. pmid:10051741 LaunchUrlCrossRefPubMed ↵ Connor, M. J. & Sidell, N. (1997) Mol. Chem. Neuropathol. 30 , 239-252. pmid:9165489 LaunchUrlPubMed ↵ Zetterstrom, R. H., Simon, A., Giacobini, M. M. J., Ericksson, U. & Olson, L. (1994) Neuroscience 62 , 899-918. pmid:7870312 LaunchUrlCrossRefPubMed ↵ Misner, D. L., Jacobs, S., Shimizu, Y., de Urquiza, A. M., Solomin, L., Perlmann, T., De Luca, L. M., Stevens, C. F. & Evans, R. M. (2001) Proc. Natl. Acad. Sci. USA 98 , 11714-11719. pmid:11553775 LaunchUrlAbstract/FREE Full Text ↵ Wagner, E., Luo, T. & Drager, U. C. (2002) Cereb. Cortex 12 , 1244-1253. pmid:12427676 LaunchUrlAbstract/FREE Full Text ↵ Matsuoka, I., Mizuno, N. & Kurihara, K. (1989) Brain Res. 502 , 53-60. pmid:2573410 LaunchUrlCrossRefPubMed Andrews, P. W., Nudelman, E., Hakomori, S. I. & Fenderson, B. A. (1990) Differentiation 43 , 131-138. pmid:2373286 LaunchUrlCrossRefPubMed Ingraham, C. A. & Maness, P. F. (1990) Dev. Neurosci. 12 , 273-285. pmid:1705209 LaunchUrlPubMed McBurney, M. W. (1993) Int. J. Dev. Biol. 37 , 135-140. pmid:8507558 LaunchUrlPubMed Bain, G., Kitchens, D., Yao, M., Huettner, J. E. & Gottlieb, D. I. (1995) Dev. Biol. 168 , 342-357. pmid:7729574 LaunchUrlCrossRefPubMed ↵ Hill, D. P. & Robertson, K. A. (1998) Brain Res. Protoc. 2 , 183-190. LaunchUrlCrossRefPubMed ↵ McCaffery, P. J., Adams, J., Maden, M. & Rosa-Molinar, E. (2003) Eur. J. Neurosci. 18 , 457-472. pmid:12911743 LaunchUrlCrossRefPubMed ↵ Ninomiya, Y., Adams, R., Morriss-Kay, G. M. & Eto, K. (1997) J. Cell. Physiol. 172 , 25-35. pmid:9207922 LaunchUrlCrossRefPubMed ↵ Guillemain, I., Fontes, G., Privat, A. & Chaudieu, I. (2003) J. Neurosci. Res. 71 , 38-45. pmid:12478612 LaunchUrlCrossRefPubMed ↵ Allenby, G., Bocquel, M., Saunders, M., Kazmer, S., Speck, J., Rosenberger, M., Likey, A., Kastner, P., Grippo, J. F., Chambon, P. & Levin, A. A. (1993) Proc. Natl. Acad. Sci. USA 90 , 30-34. pmid:8380496 LaunchUrlAbstract/FREE Full Text ↵ Kraft, J. C., Kochhar, D. M., Scott, W. J. & Nau, H. (1987) Toxicol. Appl. Pharmacol. 87 , 474-482. pmid:3470977 LaunchUrlCrossRefPubMed ↵ Idres, N., Marill, J., Flexor, M. A. & Chabot, G. G. (2002) J. Biol. Chem. 277 , 31491-31498. pmid:12070176 LaunchUrlAbstract/FREE Full Text ↵ Samad, T. A., Krezel, W., Chambon, P. & Borrelli, E. (1997) Proc. Natl. Acad. Sci. USA 94 , 14349-14354. pmid:9405615 LaunchUrlAbstract/FREE Full Text ↵ Ohtani, N., Goto, T., Waeber, C. & BConceal, P. G. (2003) J. Neurosci. 23 , 2840-2850. pmid:12684471 LaunchUrlAbstract/FREE Full Text ↵ ReynAgeds, J. N., Ryan, P. J., Prasad, A. & Paterno, G. D. (1994) Neurosci. Lett. 165 , 129-132. pmid:8015713 LaunchUrlCrossRefPubMed ↵ Neelands, T. R., Greenfield, L. J., Jr., Zhang, J., Turner, R. S. & MacExecutenald, R. L. (1998) J. Neurosci. 18 , 4993-5007. pmid:9634565 LaunchUrlAbstract/FREE Full Text ↵ Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) J. Neurosci. 22 , 5572-5580. pmid:12097508 LaunchUrlAbstract/FREE Full Text ↵ Chiang, M. Y., Misner, D., Kempermann, G., Schikorski, T., Giguere, V., Sucov, H. M., Gage, F. H., Stevens, C. F. & Evans, R. M. (1998) Neuron 21 , 1353-1361. pmid:9883728 LaunchUrlCrossRefPubMed ↵ Cocco, S., Diaz, G., Stancampiano, R., Diana, A., Carta, M., Curreli, R., Sarais, L. & Fadda, F. (2002) Neuroscience 115 , 475-482. pmid:12421614 LaunchUrlCrossRefPubMed ↵ Etchamendy, N., Enderlin, V., Marighetto, A., Vouimba, R. M., Pallet, V., Jaffard, R. & Higueret, P. (2001) J. Neurosci. 21 , 6423-6429. pmid:11487666 LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)